藥物發展的開放式創新：以公司L與委託研究機構QPS為例

簡易檢索 / 詳目顯示

回結果列表

研究生：	黎班杰 Bhor, Kanchan Hanuman
論文名稱：	藥物發展的開放式創新：以公司L與委託研究機構QPS為例 Open Innovation in Drug Development: A Case Study of Company L and QPS
指導教授：	張元杰 Chang, Yuan-Chieh
口試委員:	胡美智 Hu, Mei-Chih 許經明 Shiu, Jing-ming
學位類別：	碩士 Master
系所名稱：	科技管理學院 - 國際專業管理碩士班 International Master of Business Administration(IMBA)
論文出版年：	2018
畢業學年度：	106
語文別：	英文
論文頁數：	40
中文關鍵詞：	开放式创新、合同研究组织、制药工业、生物技术
外文關鍵詞：	Open Innovation, Contract Research Organization, Pharmaceutical Industry, Biotechnology
相關次數：	點閱：9 下載：0
分享至:	分享至facebook 分享至twitter

查詢本校圖書館目錄查詢臺灣博碩士論文知識加值系統勘誤回報

N/A

Biotech and pharmaceutical companies are struggling for drug time line and cost cutting. For opening the door of innovation, companies need to come in relationship with other organizations to share with innovative idea and expertise.
In this research work, I explore the concept of open innovation in pharmaceutical industry. Drug development goes through complex processes like drug discovery, clinical trials phases and post-marketing surveillance. For being these processes, they need to do huge investment in R & D projects. Thus, for reducing R & D cost along with product lifecycle, pharmaceutical and biotech companies need to develop an external network with different partners like contract research organizations (CROs) and universities by using both spin-in (outside in) and spin-off (inside out) open innovation. Here, I use an example of company L (pharma) and QPS (CRO) to demonstrate the processes and benefits of open innovation. Furthermore, pharma companies enter into a symbiotic relationship with biotech firms to exchange technologies and knowledge by exploring their innovation processes. This thesis also sheds light on how open innovation benefits to the pharma L and QPS.

CONTENTS
ABSTRACT    ii
ACKNOWLEDGEMENT    iii
LIST OF ABBREVIATION    iv
CONTENTS    v
LIST OF FIGURES    vii
LIST OF TABLES    viii
CHAPTER 1 INTRODUCTION    1
1.1 Research Motivation    2
CHAPTER 2 LITERATURE REVIEW    3
2.1 Open Innovation    3
2.2 Triggers of Open Innovation (Causes)    4
2.3 Closed Innovation Vs Open Innovation    5
2.3.1 Closed Innovation    5
2.3.2 Open Innovation    5
2.4 Open Innovation Processes and Model    7
2.4.1 Inside-Out Process    7
2.4.2 Outside-In Process    8
2.4.3. Coupled Process    9
2.5 Benefits of Open Innovation    11
2.6 Open Innovation in Pharmaceutical Industry    12
2.6.1 Open Innovation Element in Pharma Industry    13
CHAPTER 3 RESEARCH METHODS    16
3.1 Research Design    16
3.2 Research Materials    17
3.3 Data Collection Procedure    17
3.4 Data Analysis    17
CHAPTER 4 CASE STUDY    19
4.1 Companies Overview    19
4.1.1 Background of Company L (Pharmaceutical Company)    19
4.1.2 Background of QPS    20
4.2 Why Pharma L Need to Adapt OI?    22
4.3 Process    24
4.3.1 Adaptation of Open Innovation in Company L    24
4.3.2 IP Management    26
4.3.3 Internal Capabilities and External Network    26
4.3.4 Significant Role of QPS    27
4.4 Mutual Benefits From OI    28
4.4.1 Cutting Costs    29
4.4.2 Chasing Innovation    29
4.4.3 Opening Dedicated Knowledge and Technology    30
4.4.4 Increasing Speed and Agility    31
CHAPTER 5 CONCLUSION    32
LIMITATION    33
References    33
Appendix    36
Interview Questionnaires    36


                                

Agarwal, P. (2013). Novelty in the target landscape of the pharmaceutical industry. Nat. Rev. Drug Discovery, 12(8), 575-576.

Alexander Schuhmacher, M. H. (2016). Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation. Wiley-VCH Verlag GmbH & Co. KGaA.

Bianchi M et al. (2010). Enabling open innovation in small-and medium-sized enterprises: How to find alternative applications for your technologies. R&D Management, 40(4), 414-431.

Bianchi, M. e. (2011). Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation, 31, 22-23.

Chesbrogh et al. (2006). Open innovation: a new paradigm for understanding industrial innovation. Open innovation: Researching a new paradigm, 1-12.

Chesbrough H., W. (2003). Open innovation: The New Imperative for Creating and Profiting from Technology. Chicago: Harvard Business Press.

Chesbrough, H. (2004). Managing open innovation. Research Technology Management, 23-26.

Chesbrough, H., & Crowther, A. K. (2006). Beyond high tech: Early adopters of open innovation in other industries. R&D Management, 36(3), 229-236.

Chesbrough, W. H., & Garman, A. R. (2009). How Open Innovation Can Help You Cope in Lean Times. Harv. Bus. Rev., 87(12), 68-76.

Christensen, C. (2013). The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail, . Harvard Business Review Press.

D. Chiaroni et al. (2011). The Open Innovation Journey: How firms dynamically implement the emerging innovation management paradigm. Technovation, 31, 34-43.

Deloitte. (2015). Executing an open innovation model: Cooperation is key to competition for biopharmaceutical companies.

Gassmann & Enkel. (2004). “Towards a Theory of Open Innovation: Three Core Process Archetypes,”. R&D Management Conference, (p. 1 to 18). chicago.

Gassmann, O. E. (2010). The future of open innovation. R&D Management, 213-221.
Harvey, M. (2010). Project Management, 4th edition. Harlow: Pearson Education Ltd.

Hossain, M. (2015). A review of literature on open innovation in small and medium-sized enterprises. Journal of Global Entrepreneurship Research, 5(6), 1-12.

Khanna, I. (2012). Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug discovery today, 17(9), 1088-1102.
Manceau, D. M.-H. (2011). Open Innovation: Analysing what Open Innovation Changes in the Way Companies Innovate in terms of Partner Relationships. Internal Organization and Innovation Performance.

Michelino F. et al. (2015). Open Innovation in the Pharmaceutical Industry: An Empirical Analysis on Context Features, Internal R&D, and Financial Performances. Transactions on Engineering Management, 62(3).

Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov, 8, 959-968.

Nilsson, N. (2015). Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity. Future Med. Chem., 7(14), 1853-1859.

Paul S.M.et al. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov, 9, 203-214.

Quinn, B. J. (2000). Outsourcing Innovation: The New Engine of Growth. MIT sloan Manage. Rev, 42(4), 139-147.

Rahman H & Romos. (2010). Open innovation in SMEs: From close boundries to networked paradigm. Issues in Informing Scinece and Information Technology, 7, 471-487.

Schuhmacher et al. (2013). Models for open innovation in the pharmaceutical industry. Drug Discovery Today, 18(23-24), 1133-1137.

Shan Yu Su. (2010). How small firms can benefit from open innovation?- Evidence from Taiwanese biotechnology firms.

Van de Vrande V et al. (2009). Open innovation in SMEs: Trends, motives and management challenges. Technovation, 29(6), 423-437.

Websites
1. https://en.wikipedia.org/wiki/Clinical_trial
2. https://www.qps.com/
3. www.contractpharma.com
4. Company L website (confidential)

簡易檢索 / 詳目顯示

相關論文